Humanized monoclonal neutralizing antibody targeting metapneumovirus F protein and application thereof

By developing the human monoclonal neutralizing antibody MV32 targeting the F protein of metapneumovirus, the limitations of existing antibodies in terms of limited neutralizing activity and poor broad-spectrum activity have been overcome. This has enabled highly efficient neutralization and in vivo protection against multiple metapneumovirus strains, making it suitable for pharmaceutical compositions and detection products, and meeting the needs of clinical applications.

CN122302046APending Publication Date: 2026-06-30INST OF MICROBIOLOGY CHINESE ACAD OF SCI
1 Cites 0 Cited by

Patent Information

Application Number
CN202610417729.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-31
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Existing monoclonal antibodies targeting human metapneumovirus F protein have problems such as limited neutralizing activity, poor broad-spectrum activity, poor in vivo protective effect, and high immunogenicity risk, making it difficult to meet the needs of clinical application.

Method used

A human monoclonal neutralizing antibody (MV32) targeting the metapneumovirus F protein was developed. Its heavy and light chain variable regions contain specific complementarity-determining regions and framework amino acid sequences, enabling it to bind to the metapneumovirus F antigen with high affinity and exhibiting broad-spectrum neutralizing activity. It can be used for the prevention and treatment of human metapneumovirus infection through various routes of administration.

Benefits of technology

MV32 antibody can effectively neutralize multiple metapneumovirus strains, providing in vivo protection and prevention. It is suitable for preparing pharmaceutical compositions, detection kits, and products for the prevention and treatment of human metapneumovirus infection, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a human monoclonal neutralizing antibody targeting metapneumovirus F protein and application of the human monoclonal neutralizing antibody. The heavy chain variable region comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region comprises complementary determining regions HCDR1, HCDR2 and HCDR3 of which the amino acid sequences are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and / or, the light chain variable region comprises an amino acid sequence which has complementary determining regions LCDR1, LCDR2 and LCDR3 respectively shown as SEQ ID NO: 4, AAS and SEQ ID NO: 5, and an amino acid sequence which has complementary determining regions LCDR1, LCDR2 and LCDR3 respectively shown as SEQ ID NO: 4, AAS and SEQ ID NO: 5. The metapneumovirus monoclonal neutralizing antibody MV32 disclosed by the invention can be specifically combined with a metapneumovirus F antigen (about 0.6 nM), has relatively good broad-spectrum neutralizing activity on representative strains such as a metapneumovirus hMPV A1 strain, a metapneumovirus B1 strain and a metapneumovirus A2b strain, has certain in-vivo protection and prevention effects, can be used for preventing and treating human metapneumovirus infection, and has a good application prospect. And the method has a relatively great application prospect.
Need to check novelty before this filing date? Find Prior Art